Elena Garralda, MD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, comments on the importance of the results of the Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer
DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer Oncoinfo – Istantanee di Oncologia: seguici su At SABCS 2019 Ian Krop (Breast Oncology Center, Dana-Farber Yeon Hee Park, MD, PhD, Samsung Medical Center, Seoul, Korea, discusses findings from the Phase Ib/II Neo-PATH clinical trial
Finding appropriate doses for HER2 positive breast cancers Dr Tolaney talks to ecancer at ASCO 2025 about data she presented from the phase 3 DESTINY-Breast09 clinical trial. This found
Expert Cancer Panel: Recurrent metastatic breast cancer w/ suspected pulmonary toxicity on therapy Enhertu plus pertuzumab granted Priority Review in the US as 1st
HER2CLIMB-05: tucatinib with trastuzumab and pertuzumab as maintenance therapy for HER2+ mBC Exciting news in metastatic breast cancer! We have three press releases from 3 major studies (one for each BC subtype: triple
Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses the characterization of genomic features associated with Anti-HER2 Mechanisms of Approved HER2 Inhibitors ASCO25 Highlights: T-DXd & pertuzumab improves PFS in HER2+ metastatic breast cancer. #asco25 #bcsm
Fam-trastuzumab deruxtecan-nxki (Enhertu), both as monotherapy and in combination with pertuzumab (Perjeta), displayed encouraging efficacy Sequencing novel HER2-targeted therapies in metastatic breast cancer
The significance of HER2 expression for the activity of trastuzumab deruxtecan HER2-Positive Breast Cancer: Promising New Drug Combo
Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast Cancer In this interview, William Gradishar, MD, Northwestern University Feinberg School of Medicine, discusses how treatment Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups
Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers Breakthrough Breast Cancer Drug Combo
HER2-Positive Breast Cancer: a promising new drug combo was explored by the Destiny-Breast09 trial. This study replaced IV 32 month follow-up of MOUNTAINEER: tucatinib and trastuzumab in HER2+ mCRC
Trastuzumab Deruxtecan With Pertuzumab May Delay Cancer First-Line Enhertu Combo Gets Priority Review in HER2+ Metastatic
Alberto Montero Discusses PERTAIN Study in HER2-Positive Breast Cancer 'Massive Improvement' With Second-Line Enhertu in HER2+ Breast Cancer - Medpage Today
Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, discusses the successes of trastuzumab deruxtecan for about therapy escalation/deescalation for patients with HER2 positive breast cancer. She summarises the discussions from the ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy
Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Results showed that Enhertu plus Perjeta reduced the risk of disease progression or death by 44% compared with THP. Median progression-free People who received Enhertu and Perjeta had a 44% lower risk of the cancer growing or dying from breast cancer than people who received THP
SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03 Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, talks on new agents in the field of HER2-positive metastatic Evolving Treatment Strategies for HER2-positive Breast Cancer
Trastuzumab deruxtecan (Enhertu) is a type of HER2-targeted therapy called an antibody-drug conjugate that is made up of trastuzumab attached to Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer
Enhertu plus pertuzumab demonstrated highly statistically significant Maria Fernanda Mosele, MD, Gustave Roussy, Villejuif, France, talks on the significance of HER2 expression for the activity of Aditya Bardia, MD, MPH, FASCO, discusses standard first-, second-, and third-line HER2-positive metastatic breast cancer
Trastuzumab deruxtecan shows benefit in patients with HER2 + mBC Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the ongoing DESTINY-Gastric03 study Study: Enhertu-Perjeta Combo Slows Growth of HER2 Metastatic
Free CME/CE: HER2 is overexpressed in Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. Website:
Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on clinical developments of HER2-low breast cancer, In this update from ASCO 2025, Dr. Maryam Lustberg, Chief of Breast Medical Oncology at Yale Cancer Center, breaks down the Trastuzumab Deruxtecan for Breast Cancer | NEJM
Highlights from ESMO: DESTINY-Breast03 TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer
HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BC Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer. Website: Treatment for HER2+ metastatic breast cancer
Cristina Saura Manich, MD, PhD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, presents results from the TULIP study, Reporting from the ESMO Congress 2021, Cristina Saura describes the outstanding results from the DESTINY-Breast03 study and
How do Trastuzumab (Herceptin) and Pertuzumab (Perjeta) work for HER2-positive breast cancer? In this video, Dr. Jennifer The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least 1 dose of
Current and future HER2+, HR- metastatic breast cancer treatment approaches ENHERTU Therapy: A Powerful New Cancer Treatment Metastatic Breast Cancer Updates
Erika Hamilton, MD, from the Sarah Cannon Research Institute in Nashville, TN, presents updated findings from the Phase III Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE Neo-PATH: TAHP for patients with HER2-positive breast cancer
Earn CME for related activities: Patients whose disease progresses or relapses on trastuzumab now Trastuzumab (Herceptin) & Pertuzumab (Perjeta) for HER2+ Breast Cancer: A COMPLETE Guide
Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2-positive metastatic breast cancer, but Dr. Sara Nunnery, director of breast cancer research at Tennessee Oncology, outlines key considerations when deciding whether
Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who's the Right Patient? DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer Rupert Bartsch, MD, Medical University Vienna, Vienna, Austria, gives an overview of the current standard of care treatments for
Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer The FDA has granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab for the first-line The phase 3 DESTINY-Breast09 clinical trial showed that first-line treatment with trastuzumab deruxtecan (T-DXd) plus
Dr. Kelly McCann, of the UCLA Health David Geffen School of Medicine, shares her expert insights on sequencing therapies for Mette van Ramshorst, MD and Medical Researcher at the Netherlands Cancer Institute discusses the effect of trastuzumab-based
Dr Sara Hurvitz speaks to ecancer about the subgroup analyses from the randomised phase 3 study DESTINY-Breast03. DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1 FDA Grants Breakthrough Therapy Designation to Frontline T-DXd
Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in Effect of Trastuzumab-based Therapy on Survival in Small, Node-Negative HER2-positive Breast Cancer
Treatment Sequencing Strategies in HER2-Positive Breast Cancer Trastuzumab deruxtecan in metastatic HER2+ breast cancer HER2-low expression in breast cancer
Treatment strategies for HER2+ metastatic breast cancer Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, shares the primary results of the Phase III DESTINY-Breast02 Dr. Gradishar on Managing Toxicities and Tailoring Treatment in HER2+ mBC
Enhertu (trastuzumab deruxtecan) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in John Strickler, MD, Duke University, Durham, NC, discusses final results from the Phase II MOUNTAINEER trial (NCT03043313),
Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced b EVERYTHING you need to know About Herceptin Treatment DESTINY-Breast09 Trial Shows Enhertu Plus Perjeta Significantly
Dr Sara Hurvitz speaks to ecancer as part of SABCS 2022 about updated survival results of the randomised, phase 3 DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC? FDA Fast-Tracks Breast Cancer Drug Combo The FDA granted Breakthrough status to Enhertu + Pertuzumab for HER2+
Dr Oleg Gluz speaks to ecancer at ESMO 2024 about results from the WSG-TP-II trial. This trial evaluated endocrine therapy plus Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer
Dr Bardia on Current Approaches to HER2+ Breast Cancer Management PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, describes the rationale and study design of HER2CLIMB-05 Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses current treatments for HER2-positive, HR-positive
DESTINY-Breast07: updated results of first line T-DXd in HER2+ breast cancer Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, presents updated results from the DESTINY-Breast07 trial
Get ALL the info you need about HER2 +ve BREAST CANCER - HER2 +ve BREAST CANCER || Dr Liz O'Riordan In this video I'll Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, provides an overview of the preliminary data of the Phase Ib/II What is Enhertu? Enhertu is a new FDA approved treatment for breast cancer and other cancers. It's the first drug approved to treat
In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved progression-free survival compared to Ian Krop, MD, PhD, Smilow Cancer Hospital, Yale New Haven, CT, shares his key takeaways from the San Antonio Breast Cancer
#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer Recorded on 2/20/2021 66-year-old female with recurrent, metastatic, ER-negative, PR-positive, HER2 positive breast cancer,
Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management Trastuzumab Deruxtecan With or Without Pertuzumab Demonstrates DESTINY-Breast01: a new "destiny" for HER2positive mBC patients?
In the trial, Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% versus a taxane, trastuzumab and DESTINY-Breast03 results "will change my practice," says Amy Tiersten.
Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, provides an overview of the ongoing Phase III HER2CLIMB-05